1. Prostate imaging: Contribution of PET PSMA and MRI.
- Author
-
Abecassis JP, Ghazzar N, Peyromaure M, and Giraud P
- Subjects
- Adenocarcinoma chemistry, Adenocarcinoma diagnostic imaging, Adenocarcinoma radiotherapy, Aged, Carbon Radioisotopes, Choline analogs & derivatives, Fluorine Radioisotopes, Humans, Male, Multimodal Imaging methods, Neoplasm Recurrence, Local diagnostic imaging, Prostatic Neoplasms chemistry, Prostatic Neoplasms radiotherapy, Radiopharmaceuticals, Ultrasonography methods, Antigens, Surface, Glutamate Carboxypeptidase II, Magnetic Resonance Imaging methods, Positron Emission Tomography Computed Tomography methods, Prostatic Neoplasms diagnostic imaging
- Abstract
Prostate cancer is the most common malignant tumour and represents the third cause of cancer-mortality in men. The management of prostate cancer has dramatically changed over the last decades, mainly due to improvement of diagnostic modalities and development of new therapeutic strategies. Imaging plays a key role in all the steps of prostate cancer management. In recent years, magnetic resonance imaging (MRI) and positron-emission tomography (PET) - computed tomography (CT) have emerged as two major tools for the detection of prostate cancer, tumour staging and treatment choice. Both MRI and PET-CT - using choline or prostate-specific membrane antigen (PSMA) as radiotracer - have become mandatory. This article presents the contribution of the latest advances in these two imaging techniques of prostate cancer and their future developments., (Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF